Following an insightful panel discussion at the DIA 2024 Global Annual Meeting, this whitepaper addresses some of challenges posed by a lack of broad and complete longitudinal data and challenges that could arise in the conduct of long-term safety studies. The authors describe a hypothetical study design to overcome some of these challenges and explore other ways researchers may overcome common obstacles.

Authors

    • Naomi Boxall PhD, General Manager, PHARMO Institute

    • Nikita Jeswani MBA, Head of Global Sales, Lumanity RWE

    • Ron Herings PhD, Scientific Director, PHARMO Institute

    • Steven Weisman PhD, Global President, Lumanity Clinical and Regulatory

    • Vera Ehrenstein DSc, Professor, Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University

Read the whitepaper

Complete the form to gain access

"*" indicates required fields

Sign me up to receive regular insights from Lumanity
By selecting this box, I consent to receive Lumanity marketing communications by email.
This field is for validation purposes and should be left unchanged.